Belgium’s UCB and Teva Pharmaceutical Industries have entered into a pact which will see the two companies jointly commercialise the Israeli-headquartered firm's respiratory medicines in the USA.

In particular, the first product they intend to co-market is
Teva's asthma inhaler ProAirHFA (albuterol), which the latter says is the number-one branded hydrofluroalkane albuterol sulfate inhaler in the USA. Financial terms of the deal were not disclosed.

Teva is best known for its generics operations but is also expanded its branded business. William Marth, chief executive of Teva North America noted that "over the last months we have undertaken a rich, strategic review globally across regions, therapy areas and business units," and respiratory drugs have been identified as a key growth driver, given the incidence of asthma, allergic rhinitis, and chronic obstructive pulmonary disease”.

He added that the collaboration with UCB, “a company known for excellence in the respiratory market, will help us achieve a stronger presence in this growing therapeutic area”.

Keppra XR filing in the USA
Staying with UCB and the Brussels-based firm noted that a New Drug Application for the use of Keppra XR (levetiracetam) extended-release tablets in the adjunctive treatment of partial onset seizures in adults with epilepsy has been accepted for filing by the US Food and Drug Administration.

The company said the file is based on a Phase III study which met its primary endpoint for seizure reduction over placebo during the treatment period, with a median percentage reduction of partial onset seizures in the Keppra XR group of 46.1% compared to 33.4% with placebo. Also, 24% of patients randomised to the extended-release levetiracetam group had seizure frequency per week reduced by 75%-100%, compared with 11.4% in the placebo arm.